The market cheered Arvinas with an 11.7% jump to about $9, yet the real headline sits in the income statement. A biotech that many investors still file mentally under early stage clinical story just printed Q2 basic earnings per share of $2.61 on revenue of $249.7m, driven by licensing and collaboration flows.

Coming into the release, the stock had drifted over the past three months, with a weaker 90 day return despite modest gains in the last week and month. Today's move is the market trying to reconcile that mixed share price history with a quarter that finally looks like real profit on paper.

Impressed by Arvinas turning in positive earnings but unsure how many biotechs can keep that up without constant deal making? Check out our screen of 18 high quality undiscovered gems to compare Arvinas with other companies that pair strong fundamentals with under the radar potential.

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$249.7m vs. US$22.4m (very large increase)
• Net Income, Q2 2026 vs. Q2 2025: US$169.4m profit vs. US$61.2m loss (swing to profit)
• Basic EPS, Q2 2026 vs. Q2 2025: US$2.61 vs. a loss of US$0.84 per share (swing to profit)
• Pipeline Progress, Q2 2026 vs. Q2 2025: Phase I programs 4 vs. 5 and Phase II programs 2 vs. 4 (portfolio is more concentrated in fewer mid stage assets)

Tired of scrolling through walls of text and raw figures trying to make sense of Arvinas after this earnings swing? Get the full picture in a clear visual format that highlights the company's recent earnings profile in our company report for Arvinas.

Arvinas Bull Case Tied To Executed Milestones

Bulls argue Arvinas can turn a focused protein degradation platform into a funding engine for its pipeline. The Q2 print gives concrete support to that idea. VEPPANU is now approved, which is a key technical and regulatory milestone for the whole PROTAC class. Arvinas also converted that success into cash through the Rigel license, booking US$62.5m of license revenue and US$50m of approval related milestones from Pfizer.

The bullish story also leans on self funded development rather than constant equity raises. In this context, the US$567.9m cash balance and guided runway into H2 2028, together with lower R&D and G&A in Q2, show progress toward that goal. Management has reoriented around a smaller set of programs with clear forthcoming readouts. That supports the idea of a more capital efficient, milestone driven model, even if future revenue will be more back end loaded and tied to partners.

Compare Arvinas' internally guided runway and milestone model with how the street is reacting to this 11.7% post earnings move. See the consensus price target analysis for Arvinas to check whether analyst targets line up with that bullish earnings narrative.

Arvinas Bear Case, Milestones Still Look Fragile

The core bear worry on Arvinas is that a concentrated pipeline and milestone heavy model leaves the business exposed once one off payments fade. Q2 does not fully clear that hurdle. The US$249.7m revenue print relies heavily on license and approval related flows, and management has already confirmed there will be no further revenue from the original Pfizer collaboration. That directly supports the concern that current income is front loaded rather than recurring.

Bears also worry that program cuts and partner dependence reduce optionality. R&D fell to US$52.6m in Q2 and several assets have been pushed to partners, which helps cash runway but reinforces reliance on Rigel and Pfizer execution. Clinical timelines back that up. Key oncology and neurology readouts for ARV 393, ARV 027 and ARV 102 all sit beyond 2026. That means the milestone gap between this quarter's windfall and the next wave of data remains open.

After one quarter dominated by one off milestone revenue and insider selling in recent months, expose whether Arvinas faces deeper structural threats in our risk analysis for Arvinas which shows 3 important warning signs.

Stay Ahead Of The Next Arvinas Move

If Arvinas’ swing to a Q2 profit and milestone heavy model has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and spot an entry that fits your risk tolerance. After you are invested, use the Portfolio Command Center to cut through day to day noise and focus on the key updates that matter for your holdings. For a longer term view, tap into crowd insights and debate around Arvinas and similar stocks through the Community. By surfacing potential catalysts and risks early, Simply Wall St aims to help investors move faster and stay a step ahead of the market.

Seeking Alternatives Beyond Arvinas Today

Some of the most interesting ideas move first and get noticed later. Before the next breakout trend gains wider attention and while it matters, review these fresh stock ideas and consider your options.

• Track cash-rich companies that can keep funding growth even when momentum cools by reviewing the list of solid balance sheet and fundamentals stocks (49 results).
• Identify income opportunities before yields are compressed as prices change by checking the curated group of 7 dividend fortresses.
• Follow demand for secure, scalable digital infrastructure while it is still relatively under the radar by scanning the hand picked 21 cryptocurrency and blockchain stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.